Click here to view as a PDF.Breast Cancer –
SABCS*Mixed results for targeted agents in breast cancerCredits:
December 13, 2010
This activity reviews the results of several studies presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS) that assessed targeted therapy plus chemotherapy in patients with advanced breast cancer; these studies yielded mixed results. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.http://tinyurl.com/y96s8p5 Benefits of bevacizumab modest in metastatic disease
December 15, 2010
This activity reviews two studies presented at SABCS that showed only a limited increase in survival when bevacizumab was added to a chemotherapy regimen for patients with metastatic breast cancer. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.http://tinyurl.com/y9rtcpb
HER2 combo boosts metastatic breast cancer survivalCredits:
December 15, 2010
This activity is based on a study presented at SABCS that shows that a dual biologic attack on heavily pretreated metastatic breast cancer with lapatinib and trastuzumab may substantially prolong survival, without chemotherapy or endocrine therapy. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.www.medpagetoday.com/MeetingCoverage/ SABCS/17536
Vitamin D reduces aromatase inhibitor pain
NoneExpires: December 15, 2010
This activity is based on a study presented at the 2009 American Society of Hematology (ASH) annual meeting that indicated that a highdose of vitamin D might relieve musculoskeletal pain caused by treatment of breast cancer with aromatase inhibitors. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.
*More SABCS CME opportunities are available at medpage Today at www.medpagetoday.com/ MeetingCoverage/SABCS.
Colorectal Cancer –
Surgical approach to liver-limited metastatic colorectal cancerCredits:
September 15, 2010Multimedia:
Participants are required to read an E-Update in which experts write about recent liver-limited colon cancer advances. The update discusses biologic, surgical, and toxicity issues in liver-limited disease. Successful completion of a posttest with a passing score of 80% or better earns the participant the credits. The activity in its entirety should take approximately 2 hours to complete. http://tinyurl.com/yae5rj6
Kidney Cancer – Management of small renal masses: What is the best management option in this case? Credits:
January 21, 2010Multimedia:
At the conclusion of this activity, participant will be able to contrast the benefits and pitfalls of specific management options for patients that present with an incidental renal mass, including radical nephrectomy, partial nephrectomy, energy ablation, and active surveillance; discuss the potential morbidity associated with active surveillance strategies, including the risk of local and metastatic progression; and explain issues of patient selection for appropriate management for a small renal mass.http://tinyurl.com/ye8g6w5 Innovations and challenges in renal cancer Credits:
Following completion of this activity, participants should be able to discuss how recognized molecular targets in renal cancer are related to prognosis and current and future therapeutic approaches; discuss current approaches to prognostic classification in renal cancer as they relate to treatment selection and expectation; and assess recent clinical data for immunotherapies and targeted and anti-angiogenic therapies in renal cancer treatment.
Lung Cancer – Management of stage III, N2 NSCLC: A virtual thoracic oncology tumor boardCredits:
June 30, 2010